DNL593
What it is & what research shows
Reference overviewDNL593 is an investigational protein therapy designed to transport progranulin into the brain. The program targets frontotemporal dementia associated with GRN mutations and progranulin deficiency. Early healthy-volunteer research reported dose-dependent increases in cerebrospinal-fluid progranulin. The phase 1/2 patient program continues, with results expected in 2027 in the August 2026 update. [1.1][1.2]
Increased protein in cerebrospinal fluid supports delivery, not a demonstrated improvement in memory or daily function. This genetically defined dementia program should not be generalized to all Alzheimer’s disease or healthy-person cognition. A source-linked study result with a verified dose and schedule is not yet available in this overview. This is a gap in this page, not a claim that no research exists. [2.1][2.2]
Sources & reading scope
- [1.1] DNL593: early healthy-volunteer resultsSponsor report · CSF progranulin increases support delivery; clinical benefit was not demonstrated.
- [1.2] DNL593: August 2026 development updateSponsor report · Phase 1/2 FTD-GRN study continues; patient results expected in 2027.
- [2.1] DNL593: early healthy-volunteer resultsSponsor report · CSF progranulin increases support delivery; clinical benefit was not demonstrated.
- [2.2] DNL593: August 2026 development updateSponsor report · Phase 1/2 FTD-GRN study continues; patient results expected in 2027.
Study-summary coverage
No completed study summaries are linked to this compound page yet. This is a coverage gap on PED Evidence, not evidence that human studies or other research do not exist.
Filter, save and compare DNL593 studies →Studies & trial records
Original papers, trial registrations and sponsor disclosures are labeled separately. Multiple links may describe the same study.
More about DNL593: identity, safety & reference details
Also known as DNL-593 · TAK-594 · PTV:PGRN
Start with the research
An outcome-specific synthesis has not been prepared for this compound. This is a coverage gap, not evidence that it has no effect.
Open studies and trial records- Uses & research
Early healthy-volunteer research reported dose-dependent increases in cerebrospinal-fluid progranulin. The phase 1/2 patient program continues, with results expected in 2027 in the August 2026 update. [1][2]
- Known half-life
No source-verified value in this profile yet. A treatment schedule or duration of an effect is not a drug half-life.
Half-life describes how quickly the measured drug concentration falls by half. It does not set a dosing interval.
Safety & evidence boundaries
Increased protein in cerebrospinal fluid supports delivery, not a demonstrated improvement in memory or daily function. This genetically defined dementia program should not be generalized to all Alzheimer’s disease or healthy-person cognition.
Explore safety questions by system
These are literature filters, not claims that this compound causes each effect. A keyword match is not a confirmed adverse reaction.
Identity, names & formulations
Canonical compound: DNL593 · dnl593
Searchable names: DNL-593, TAK-594, PTV:PGRN
Names share a parent research page. Different esters, salts, routes and brands are not assumed to have the same half-life, indication or exposure.
Combination evidence stays attached to the studied combination. It is not automatically assigned to each ingredient.
Understand the evidence types
Read the model and design first, then the population, outcome and limitations. These categories describe evidence, not a best-compound ranking.
- Randomized human trials
- Compare assigned interventions. Randomization does not by itself establish low bias or relevance to every population.
- Controlled human studies
- Use a comparison group; allocation and confounding still matter.
- Prospective human research
- Follows participants forward. It may be observational or interventional, so this is not a separate quality grade.
- Observational human research
- Describes associations. Confounding can explain differences.
- Case reports and series
- Useful for unusual events and safety signals, not reliable rates or effect sizes.
- Animal research
- Can test biology and function in a living model. Human exposure, benefit and safety remain separate questions.
- Cell and tissue research
- Tests responses in a preparation, including human-derived cells. It is not a human participant trial.
- Mechanistic and computational evidence
- Helps explain or predict a pathway; predictions need experimental and clinical testing.
- Anecdotal reports
- Self-reported experiences can generate questions. Product identity, selection bias and other interventions may be uncontrolled.
Systematic reviews synthesize studies and depend on their quality. Preprint status and abstract versus full-paper reading are separate labels. Citation popularity measures attention, not reliability. A study summary is not a formal quality appraisal.
Sources for this profile
- 1. DNL593: early healthy-volunteer results Sponsor report · CSF progranulin increases support delivery; clinical benefit was not demonstrated.
- 2. DNL593: August 2026 development update Sponsor report · Phase 1/2 FTD-GRN study continues; patient results expected in 2027.
Reference facts checked 2026-09-24. Source scope is listed above; this is not a formal quality appraisal. See each label for full prescribing information.
Study model describes the source. Confidence depends on methods, replication, population and outcome.
Loading compound research…